NL-OMON38050招募中不适用
A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients with Advanced Solid Cancers - NP25448, TWEAK inhibitor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Histologically or cytologically confirmed malignant solid tumors that are refractory or resistant to available therapies, or for which current therapy is not considered to provide benefit.;2) Patients must have measurable and/or evaluable disease;3) Tumor expression of the Fn14 receptor;4) Age >= 18 years;5) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;6) Estimated life expectancy of >= 12 weeks;7) Adequate bone marrow function, defined as ANC >=1.5 x 109/L, platelets > 100 x 109/L, and hemoglobin >=9.0 g/dL (5.6 mmol/L);8) Adequate liver function, defined as total bilirubin <1.5 x ULN, AST and ALT <= 2.5 x ULN (<= 5x ULN with hepatic metastases), and serum bilirubin <= 2.5 mg/dL (43 umol/L);9) Adequate renal function, defined as serum creatinine < 1.5 mg/dL (132 umol/L) or creatinine clearance estimate >=60 mL/min [1.00mL/s/m2] (according to Cockroft-Gault formula, Appendix 5) ;10) Women of childbearing potential and women less than 2 years after menopause must have a negative pregnancy test result within 72 hours prior to receipt of study treatments.;11) Patients must be willing to use effective methods of contraception throughout study participation and for at least 90 days after the last dose of study medication.
- •Female patients must be postmenopausal, surgically sterile, or agree to use physical barrier method of contraception. Oral or injectable agents must not be the sole method of contraception. Male patients must be surgically sterile or agree to use barrier method of contraception. ;12) Patients (or legal representative) must be willing and able to provide written informed consent.;13) Patients must be able and willing to comply with protocol requirements as determined by the study investigator. This includes study requirements for clinic visits, safety assessments, and consent for paired tumor biopsies as defined in Section 2.2 of the study protocol.
排除标准
- •1) Treatment with any investigational agent within 21 days prior to first dose of study treatment ;2) Prior chemotherapy, radiotherapy, or hormonal therapy for cancer within 3 weeks of first study treatment ;3) Receipt of antibody therapy or other immunotherapy currently or less than 21 days prior to study treatments, including interferons a or β, IL-2, etanercept, infliximab, adalimumab, golimumab, certolizumag pegol, cyclosporine, tacrolimus, and alefacept;4) Current immunosuppressive therapy, including those prescribed for organ transplantation and rheumatologic disease ;5) Corticosteroid therapy except for physiologic replacement dosages;6) Patients who have not recovered (> grade 1 NCI CTCAE severity) from prior adverse events related to any cancer therapy. An exception is made for alopecia. ;7) Pregnant or breast feeding women;8) Surgical procedure or clinically significant trauma within three weeks of study treatments. ;9) Known hypersensitivity to any component of RO5458640 or patients with previous severe hypersensitivity reactions to monoclonal antibody therapy.;10) History of active seizure disorder (event <= 2 months prior to study initiation or seizures not controlled with medication).;11)History of CNS or leptomeningeal metastases, except clinically stable disease characterized by ALL of the following: a) surgical resection or radiotherapy completed >= 3 months prior to first study drug, b) no corticosteroid requirements for >= 4 weeks prior to first study drug, c) stable CNS disease assessed by CT or MRI within 4 weeks of study drug, d) stable neurologic exam (no new focal or global abnormalities) for at least 4 weeks prior to first study drug. To confirm eligibility, a discussion between the Investigator and Sponsor is required for patients with CNS tumor. ;12) Serious cardiovascular illness, including but not limited to a) CVA or MI within 6 months of study initiation, b) CHF >= NYHA Class 2, unstable angina, symptomatic or otherwise uncontrolled arrhythmia requiring medication (does not include stable, lone atrial fibrillation), QTcF > 480 msecs (Fredericia correction method will be the primary evaluation parameter throughout the study), or uncontrolled hypertension;13) Active infection;14) Other uncontrolled, concurrent disease, including diabetes mellitus, pulmonary (clinically significant hypoxia requiring chronic, supplemental oxygen therapy), or altered mental status or psychiatric illness that would limit compliance with study requirements;15) A physical exam or laboratory finding that contra-indicates the use of investigational therapy or otherwise places the patient at excessively high risk for treatment, as determined by the study investigator. A discussion between the Investigator and Sponsor regarding eligibility is encouraged for such cases.
研究者
相似试验
进行中（未招募）
1 期
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid TumorsEUCTR2016-001046-26-Outside-EU/EEAF. Hoffmann-La Roche AG58
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40
撤回
不适用
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON46750Biogen3
已完成
不适用
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisNL-OMON55647Biogen3
已完成
1 期
A Phase I Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy Elderly SubjectsPostherpetic NeuralgiaACTRN12610000620022Spinifex Pharmaceuticals Pty Ltd32